12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,654,445 | $78,199,950 | 0.57% | |
| 2. | Partner Fund Management Christopher Medlock James | 2,399,545 | $70,690,596 | 3.33% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,533,969 | $45,190,727 | +501% | 0.09% |
| 4. | Logos Capital Arsani William | 1,250,000 | $36,825,000 | -25% | 4.91% |
| 5. | Citadel Investment Group Ken Griffin | 1,231,824 | $36,289,535 | +37% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | Director | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | Large Shareholder | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | Large Shareholder | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | Large Shareholder | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | Large Shareholder | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.99 | 12,500 | Officer, Director | 441,417 | 2023-11-30 | Filing | |
| $34.57 | 12,500 | Officer, Director | 441,417 | 2023-11-15 | Filing | |
| $35.40 | 2,500 | Officer | 150,664 | 2023-11-09 | Filing | |
| $32.17 | 12,500 | Officer, Director | 441,417 | 2023-10-30 | Filing | |
| $33.70 | 12,500 | Officer, Director | 441,417 | 2023-10-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,634,740 | $460,599,440 | 0.01% | |
| 2. | 11,990,824 | $353,249,689 | 0.03% | |
| 3. | 10,743,324 | $316,498,325 | 0% | |
| 4. | 7,986,356 | $235,278,049 | 0.04% | |
| 5. | 5,274,486 | $155,386,358 | 0% |
News See All
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Third Quarter 2023 Conference Call.
10 Biotech Stocks with Biggest Upside
In this article, we discuss 12 biotech stocks with biggest upside.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Second Quarter 2020 Conference Call.
10 Best Economic Recovery Stocks to Buy
In this piece, we will take a look at the ten best economic recovery stocks to buy.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2023 Earnings Call Transcript
Operator: Good afternoon and welcome ladies and gentlemen to Cytokinetics' First Quarter 2023 Conference Call.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome ladies and gentlemen to Cytokinetics' Fourth Quarter 2022 Conference Call.
Is Cytokinetics (CYTK) a Good Long-Term Investment?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Is Cytokinetics, Inc. (CYTK) Going to Burn These Hedge Funds?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in...
Billionaire Hedge Funds
